Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/02/2016 12/05/2016 12/06/2016 12/07/2016 12/08/2016 Date
41.57(c) 41.24(c) 41.81(c) 40.28(c) 40.805(c) Last
1 591 746 2 344 190 1 483 499 1 611 174 1 574 210 Volume
-0.02% -0.79% +1.38% -3.66% +1.30% Change
More quotes
Financials ($)
Sales 2016 41,1 M
EBIT 2016 -429 M
Net income 2016 -406 M
Finance 2016 581 M
Yield 2016 -
Sales 2017 51,2 M
EBIT 2017 -455 M
Net income 2017 -452 M
Finance 2017 554 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 69,9x
EV / Sales2017 56,7x
Capitalization 3 457 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.The... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
12/08 ALNYLAM PHARMACEUTICALS : to Webcast R&D Day
12/08 ALNYLAM PHARMACEUTICALS : Patent Issued for Compositions and Methods for Inhibit..
12/05 ALNYLAM PHARMACEUTICALS : Presents Updated Results from Phase 1/2 Study of ALN-C..
12/04 ALNYLAM PHARMACEUTICALS : Reports Positive Interim Clinical Results for Fitusira..
12/03 ALNYLAM PHARMACEUTICALS : Reports Positive Interim Phase 1 Results for Fitusiran..
12/03 ALNYLAM PHARMACEUTICALS : Reports Positive Initial Clinical Activity Results for..
11/22 ALNYLAM PHARMACEUTICALS : and The Medicines Company Announce Publication of Phas..
11/22 ALNYLAM PHARMACEUTICALS : Announces Sanofi Genzyme Opt-in Decision for Co-Develo..
11/15 ALNYLAM PHARMACEUTICALS : The Medicines Company and Alnylam Pharmaceuticals Pres..
11/14 ALNYLAM PHARMACEUTICALS : Announces Sanofi Genzyme Opt-in Decision for Co-Develo..
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
12/05 28 Stocks For December 2016
12/04 Alnylam's fitusiran shows treatment effect in mid-stage hemophilia study
11/21 Clinical Analysis Of ALNY's Next-Gen Lipid-Lowering Therapy
11/18 Arbutus Biopharma Corporation Is Poised To Catch Up In The Hepatitis B Race
11/16 The Trump-Bump In Biotech
Advertisement
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEU...
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 62,4 $
Spread / Average Target 55%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Barry E. Greene President
Michael W. Bonney Chairman
Yvonne Greenstreet Chief Operating Officer & Executive Vice President
David-Alexandre Gros Chief Financial Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICAL..-57.21%3 457
INCYTE CORPORATION-5.98%19 208
QUINTILES IMS HOLDINGS..12.04%18 939
CELLTRION, INC.--.--%9 932
LONZA GROUP AG9.44%9 350
SEATTLE GENETICS, INC.45.03%9 214
More Results